Lung and other thoracic tumours
Read more
A pathway from air pollution to lung cancer in non-smokers has been identified
In a study presented at ESMO Congress 2022, air pollution is shown to drive interleukin-1β release in cells with EGFR mutations to promote lung cancer development
Cancer Immunology and Immunotherapy
Read more
TILs confirm to prolong PFS compared with immunotherapy in advanced melanoma
In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment
Sarcomas
Read more
First positive phase III data for a gamma secretase inhibitor in desmoid tumours
Nirogacestat improves progression-free survival in a randomised trial performed in desmoid tumours
Genitourinary cancers
Read more
Adjuvant immunotherapy does not improve disease-free survival in renal cell carcinoma
IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy?
Lung and other thoracic tumours
Read more
Could anti-PD-L1 be the best choice as front-line therapy in platinum-ineligible patients with NSCLC?
Findings show overall survival benefits with front-line atezolizumab versus single-agent chemotherapy, but questions remain regarding who might benefit
Don't miss
-
Molecular Analysis for Precision Oncology Congress
14-16 October 2022
EDITORIAL
Can new routes of administration have a place in the application of immunotherapy?
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients
Genitourinary cancers
Prostate cancer: data support adding ADT for patients undergoing post-operative radiotherapy
Results from the RADICALS-HD and PRESTO trials show encouraging metastasis-free and biochemical progression-free survival benefits with androgen deprivation therapy, but they are not practice-changing yet
First-line triplet of TKI plus dual immunotherapy improves outcomes in renal cell carcinoma
Results from the COSMIC-313 trial show that adding cabozantinib to nivolumab plus ipilimumab prolongs progression-free survival, but also increases toxicity
Gastrointestinal cancers
Intensive follow-up and ctDNA screening may improve detection of early recurrence in CRC patients
Patients with resected stage II–III CRC may benefit from earlier detection of recurrence, enabling more to receive surgery with curative intent, but further work is needed to determine the most reliable and cost-effective methods of follow-up
Potential new treatment options for metastatic colorectal cancer emerge from two studies
Encouraging clinical activity was reported for fruquintinib and the combination therapy of trastuzumab plus tucatinib in heavily pre-treated patients with manageable safety profiles
Antibody–drug conjugates show potential in advanced solid tumours
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies
NECs: mixed results for second-line therapy after progression
The optimal chemotherapy regimen in this setting is not well-defined
Jarushka Naidoo
Peter Dubsky
John Haanen